Introduction
Vascular oxidative stress is a leading cause in cardiovascular disease pathology. 1, 2 More recent data revealed a close correlation between oxidative stress and inflammation in the vasculature suggesting site-specific antiinflammatory treatment as a therapeutic strategy. [1] [2] [3] [4] Obesity, a risk factor in cardiovascular disease, is associated with increased oxidative stress and inflammation-triggered vascular dysfunction. 5 † The first three authors contributed equally to the study.
The tumour necrosis factor (TNF) superfamily member CD40 ligand (CD40L, CD154) 6 contributes to enhanced platelet function in patients with acute coronary syndrome 7 and arterial hypertension, 8, 9 controls inflammation and atherosclerosis in hypercholesterolemic mice [10] [11] [12] and contributes to arterial thrombus formation. 11, 13, 14 We recently showed that CD40L-deficient mice are protected from ATII-induced arterial hypertension. 15 Obesity caused by increased energy intake and decreased energy expenditure has risen tremendously within the last decade across the globe and became an epidemic. Obesity is accompanied by a low-grade, chronic inflammation in metabolic tissues and closely associated with an increase in cardiovascular diseases. 16 Understanding the biological basis of obesity-related pathologies and discovering interference points to restore metabolic function is therefore an urgent need. Extending on our observations in arterial hypertension 15 we investigated the role of the CD40L axis in experimental hyperlipidemia and obese patients.
Materials and methods

Animals and treatment protocol
Animal treatment was in accordance with the Guide for the Care and Use of Laboratory Animals as adopted and promulgated by the US National Institutes of Health and was approved by the Ethics Commission according to the German Law on the Protection of Animals (Landesuntersuchungsamt Rheinland-Pfalz, Koblenz, Germany: no. 23 177-07/G 11-1-020 and extension from June 2016). CD40L
-/-knockout mice (C57BL/6 background, B6.129S2-Cd40lgtm1Imx/J, Jackson Stock Number: 002770) were generated as described previously and C57BL/6 mice were used as the corresponding wild type (WT) controls (age 9 ± 1 weeks). Mice that had been fed with high fat diet (HFD: 34% fat, 1.25% cholesterol) for 16 weeks were sacrificed by exsanguination under isoflurane anaesthesia (5% in room air) and the thoracic and abdominal aorta, the blood and the heart were collected for analyses as reported. 15 In another study a total number of 18 db/db mice (BKS.CgDock7mþ/þLeprdb/J) and respective 18 control mice (BKS.CGTemoin) at an age of 12 weeks (Charles River, Sulzfeld, Germany) were either treated or not treated for 2 weeks with a CD40/TRAF6 inhibitor at a dose of 2.5 mg/kg/d (10 mmol/kg/d) (compound 6877002, BioTechne (Tocris), Wiesbaden, Germany) in DMSO by osmotic minipumps (Alzet, model 1002) s.c. implanted under ketamine/xylazine anaesthesia (1 ml/kg of a ready to use solution containing 80 mg/ml ketamine and 12 mg/ml xylazine, Sigma-Aldrich). Compound 6877002 was previously reported to decrease insulin resistance and tissue inflammation in a model of HFD-induced obesity. 17 
HFD and reagents
High fat (34%) and high cholesterol (1.25%) containing diet was purchased from Ssniff Spezialdiäten GmbH (Soest, Germany). All other chemicals and reagents of analytical grade were purchased from SigmaAldrich, Fluka and Merck.
Isometric tension studies
Vasodilator responses to acetylcholine (ACh) or nitroglycerin (GTN, Nitrolingual infusion solution, Pohl-Boskamp, Hohenlockstedt, Germany) were assessed with endothelium-intact isolated mouse aortic rings (thoracic aorta, 3 mm in length) mounted for isometric tension recording in organ chambers, as described previously 15 . For ACh a concentration-relaxation curve was determined (1 nM to 3.3 mM), for GTN maximal relaxation in response to a single bolus of 33 mM was determined.
Heart and vascular superoxide production
Superoxide levels were analysed in heart membrane fractions by lucigenin (5 mM)-enhanced chemiluminescence in the presence of nicotinamide dinucleotide phosphate (NADPH) (200 mM) using a Lumat LB9507 from Berthold Technologies (Bad Wildbad, Germany). 18 Vascular ROS formation (mainly superoxide) was determined by dihydroethidine (1 mM)-dependent fluorescence microtopography in aortic cryo-sections as previously described in. 15 In db/db mice the effect of L-NAME (0.5 mM) on endothelial ROS formation was assessed by dihydroethidine (1 mM)-dependent fluorescence microtopography in aortic cryosections. Whole blood leukocyte-dependent ROS formation was measured in fresh blood (in citrate tubes) upon dilution 1: 50 in PBS with calcium and magnesium (1 mM) and stimulation with the phorbol ester PDBu (10 mM) and assessed with L-012 (100 lM) enhanced chemiluminescence (ECL) using a Centro chemiluminescence plate reader (Berthold, Bad Wildbad, Germany). 19 
Reverse transcription real-time PCR
mRNA expression was analysed by real-time PCR (qRT-PCR) as previously described in. 15, 20 Briefly, total RNA from mouse aorta was isolated using the RNeasy Fibrous Tissue Mini Kit (Qiagen, Hilden, Germany), and 250 ng of total RNA was used for qRT-PCR analysis with the QuantiTect Probe RT-PCR kit (Qiagen). TaqMan Gene Expression assays for human or mouse TATA box-binding protein (TBP) as a reference gene, Gpx1, Sod1, catalase, iNOS, CD11b, CD68, CD40L, IL-6, IFN-c, Nox1, Nox4, VCAM-1, and ICAM-1 were purchased as probe-and-primer set (Applied Biosystems, Foster City, CA). The comparative DDCt method was used for relative mRNA quantification. Gene expression was normalized to the endogenous control TBP mRNA (One-step PCR), and the amount of target gene mRNA expression in each sample was expressed relative to control (DDCt).
Immunoblotting
Isolated tissue was frozen and homogenized in liquid nitrogen. 15 mg of total aortic protein was separated by SDS-Page, blotted onto nitrocellulose membranes and immuno-stained as described previously in. 12, 13 Dot blot was performed by phosphate-buffered saline-based transfer of 100 mg of plasma protein on PVDF membranes and the same anti-body incubation procedures like in Western blotting were used. Rabbit polyclonal antip47 phox (dilution 1:500), mouse monoclonal anti-NOX-2 (dilution 1:500), rabbit polyclonal anti-P(Ser1177)-endothelial nitric oxide synthase (eNOS) (dilution 1:500), mouse monoclonal anti-eNOS (dilution 1:1000) were purchased from BD Biosciences (USA), mouse monoclonal anti-AGE (dilution 1: 1000) was purchased from Transgenic Inc. (USA) and rabbit polyclonal anti-RAGE (dilution 1:1000) was purchased from Cell Signaling (USA). Mouse monoclonal anti-a-actinin was used as a control for loading and transfer (dilution 1: 2, 500, Sigma-Aldrich, Germany). 3-nitrotyrosine (3NT)-positive proteins in serum samples, IL-6 levels in plasma and IL-1b levels in whole blood were assessed by dot blot analysis. 
Flow cytometry
Platelets surface staining was performed in citrated whole blood for 30 min by using CD62P-FITC (1: 200 in PBS, BD Pharmingen). Analysis was performed by using a FACS Canto II flow cytometer and FlowJo Software (Tree Star). Table S1 ). mRNA expression was directly analysed using the nCounter Elements Technology (nanoString Technologies, Seattle, USA), which does not include any further enzymatic amplification. 22 Total RNA from human Aorta ascendens was isolated using the RNeasy Fibrous Tissue Mini Kit (Qiagen, Hilden, Germany). RNA integrity control and the nCounter Technology analysis were performed by the nCounter Core Facility (Institute of Human Genetics, Heidelberg University Hospital). RNA integrity was assessed using the Agilent RNA 6000 Nano Kit, provided by Agilent Technologies on a Bioanalyzer system (Santa Clara, USA) and RNA samples failing in this assay were excluded from further analysis. Customized probe sets for the following human genes were all designed by nanoString Technologies upon request; and the target-specific probes were generated by Integrated DNA Technologies (Coralville, USA): TNF, NOX-1, NOX-4, p22phox, p67phox, VCAM-1, ICAM-1, IL-6, SELP, CD68, CD11b, CD40, CD40L, tissue factor, IFNc, TRAF2, and TUBB3. In addition, probe sets to detect the following human reference genes were designed and generated by the same suppliers: HPRT, GAPDH, TBP, ACTB, TRAF6, and ACTN. Hybridization of the probe sets to their specific RNA target followed by detection of Elements Tag Sets allowed for the digital counting of the target molecules, and thus reflecting gene expression termed 'code counts'. As recommended by the manufacturer [http://www.nano string.com/media/pdf/MAN_nCounter_Gene_Expression_Data_Analysis_ Guidelines.pdf (2017, date last accessed)] the detected code counts of the analysed genes were normalized to the geometric mean of the intensities of the above-mentioned reference genes after background subtraction using the nSolver 2.0 software (NanoString Technologies, USA). The expression of the respective target gene mRNA in obese individuals was presented as a ratio to that in normal weighted ones. Detailed information on target-specific probe sets used in this technique is provided in the Supplementary material online, Table S2 .
ELISA
Quantikine ELISA Immunoassays were performed according to the manufacturer's instructions and were obtained from R&D Systems: Human CCL5/RANTES (Catalog Number DRN00B), human IL-6 (Catalog Number D6050), human CD40L/TNFSF5 (Catalog Number DCDL40).
Statistics
Results are expressed as mean ± SEM. 
Results
CD40L-deficiency attenuates weight gain, and improves blood cholesterol levels in mice under HFD
Food uptake was marginally different in WT and CD40L -/-mice ( Figure 1A) . HFD increased body weight, non-fasting serum leptin levels, total cholesterol, LDL, and HDL in WT mice, an effect that was less pronounced in CD40L -/-mice ( Figure 1B-F) . Of note, body weight was already slightly but significantly decreased in untreated CD40L -/-mice when compared with WT mice. In contrast, only minor changes in non-fasting blood glucose and triglycerides were observed (see Supplementary material online, Figure S1 ). Aortic CD40L gene expression was increased in WT mice on HFD but was not detectable in CD40L -/-mice ( Figure 1G ).
CD40L deficiency ameliorates HFDassociated endothelial dysfunction and vascular oxidative stress
Endothelial function measured by aortic ring isometric tension recordings was significantly impaired in HFD-fed WT mice, whereas no loss of endothelial function was observed in HFD-fed CD40L -/-mice ( Figure 2A ).
In contrast, HFD impaired endothelium-independent vasoconstriction in response to nitroglycerin by trend in WT mice and significantly in CD40L -/-mice (see Supplementary material online, Figure S2 ).
Vasoconstriction was neither changed significantly upon KCl nor upon PGF 2a additions in any of the groups (see Supplementary material online, Figure S2 ). revealed a HFD-induced increase of ROS formation in WT mice, which was almost absent in CD40L -/-mice ( Figure 2B ). DHE-staining in the HFD group was suppressed by the NADPH oxidase inhibitor VAS2870 and the superoxide scavenging enzyme PEG-SOD. At the same time cardiac membranous ROS formation detected by lucigenin, which was previously used for NADPH oxidase activity measurements, was significantly increased by HFD in WT mice but not in CD40L -/-mice ( Figure 2C) .
Furthermore, untreated CD40L -/-mice had a decreased membranous ROS formation compared to WT animals. The contribution of NADPH oxidase to this membranous ROS signal was supported by the protein expression of Nox2 and p47 phox (phagocytic NADPH oxidase subunits), which showed a three-to four-fold increase in animals on HFD ( Figure  2D , E). CD40L-deficiency ameliorated this upregulation and Nox2 expression was per se lower by trend in CD40L -/-mice.
CD40L deficiency attenuates the expression of inflammatory markers and platelet activation in hyperlipidemic mice
iNOS gene expression in aortic tissue increased in HFD-fed WT but not CD40L -/-mice ( Figure 3A) . Surface expression of CD62 (P-selectin) was increased on platelets of WT mice on HFD and this effect was absent in the CD40L -/-group ( Figure 3B and see Supplementary material online, Figure S3 ). Aortic mRNA content of CD11b and CD68 was increased by trend in HFD-fed WT mice, indicating increased vascular infiltration of myelomonocytic cells in general and macrophages in particular ( Figure  3C ). This trend was less pronounced in the CD40L -/-groups. HFD feeding induced no significant changes in Nox1 gene expression, whereas Nox4 mRNA levels were significantly decreased in HFD-fed WT but not 
CD40L
-/-mice ( Figure 3C ). IL-6 plasma protein levels were increased in HFD-fed WT but not in CD40L -/-mice ( Figure 3D ).
3.4
Diabetic db/db mice show increased markers of inflammation, oxidative stress and endothelial dysfunction and improvement by CD40/TRAF6 inhibitor therapy Type 2 diabetic db/db mice were used as a second model of obesity/ hyperglycemia with a severe vascular and metabolic phenotype. Food uptake was increased in db/db mice as compared with non-diabetic controls and not affected by CD40/TRAF6 inhibitor therapy with compound 6877002 in the WT mice but marginally decreased in db/db mice ( Figure 4A) . Weight gain and glycemic state (HbA1c) were increased in db/db mice and were slightly but significantly improved by CD40/TRAF6 inhibition in db/db mice ( Figure 4B, D) , whereas total body weight was not changed by CD40/TRAF6 inhibition (see Supplementary material online, Figure S4A ). Leptin serum levels were increased in db/db mice and not affected by compound 6877002 therapy ( Figure 4C) . The interpretation of the leptin data is complicated by the fact that leptin levels are dysregulated in the db/db mice due to leptin receptor deficiency. Endothelial function was largely impaired in db/ db mice and improved by trend by CD40/TRAF6 inhibition ( Figure 4E ). Endothelium-independent vasoconstriction in response to nitroglycerin was impaired significantly in db/db mice and improved by trend by CD40/TRAF6 inhibition (see Supplementary material online, Figure  S4 ). Vasoconstriction among the groups was not changed significantly upon KCl challenges but significantly increased in the db/db groups upon PGF 2a additions (see Supplementary material online, Figure S4 ). Oxidative burst in whole blood, reflecting the number and activation state of blood leukocytes, was increased in db/db mice and partially decreased by compound 6877002 therapy ( Figure 4F) . Endothelial DHE staining, as a marker of endothelial ROS formation, was increased in aortic cryo sections of db/db mice and normalized by compound 6877002 therapy ( Figure 4G ). Of note, the NOS inhibitor L-NAME decreased endothelial DHE staining in db/db mice by trend (in support of eNOS uncoupling), whereas in all other groups it increased endothelial DHE staining at least by trend (indicating functional eNOS). The markers of inflammation and oxidative stress, IL-1b in whole blood and 3NT-positive proteins in serum, respectively, were increased in db/db mice and normalized by CD40/TRAF6 inhibition ( Figure 4H, I ). In support of the observed increased oxidative stress in db/db mice, the expression of the anti-oxidant enzymes Gpx1 and catalase were decreased in the aorta of db/db mice and slightly upregulated by CD40/TRAF6 inhibition, whereas Sod1 gene expression was not changed significantly (see Supplementary material online, Figure S5 ). Cardiac protein expression of Nox2, RAGE and AGE-positive proteins were increased by trend in db/db mice and CD40/TRAF6 inhibition normalized RAGE expression in db/db mice, whereas Nox2 and AGEpositive proteins were only decreased by trend in the inhibitor group (see Supplementary material online, Figure S6 ). 
Obese patients show increased vascular inflammatory gene expression and increased sCD40L serum levels
Initial screening by nCounter (nanoString) analysis in human Aorta ascendens revealed an increase in inflammatory gene mRNA expression in the samples of obese patients compared with lean controls ( Figure 5A) . The same tissue samples were investigated by RT-PCR analysis. In particular, CD40L, IL-6, IFN-c, NOX-1, VCAM-1, and ICAM-1 were significantly increased, confirming the preliminary data obtained by nCounter (nanoString) analysis ( Figure 5B) . Interestingly, NOX-4 mRNA expression levels were by contrast reduced ( Figure 5B) . In the serum, sCD40L levels were significantly elevated, whereas IL-6 and RANTES were only increased by trend in obese patients ( Figure 5C -E).
Discussion
We here show that CD40L is critically involved in the development of hyperlipidemia/obesity-associated vascular oxidative stress, inflammation, endothelial dysfunction and platelet activation, despite unaltered food uptake of CD40L -/-mice. We further demonstrate that obesity drives increased sCD40L serum levels and increased vascular pro-inflammatory gene expression in obese human subjects. The present data support our recent findings on protective effects of CD40L deficiency in AT-II induced arterial hypertension. 15 Besides obesity and hyperlipidemia, arterial hypertension is another major risk factor for cardiovascular disease. [2] [3] [4] [5] Both obesity and hypertension trigger vascular inflammation and oxidative stress followed by endothelial dysfunction and atherosclerosis, and these parameters are ameliorated in a model of arterial hypertension by CD40L deficiency. 15 In humans, levels of several inflammatory mediators are altered in obesity, such as C-reactive protein, TNF, IL-6, IL-1b, and monocyte chemoattractant protein 1 (MCP-1), 23, 24 which was underlined by the results of our study cohort and accompanied by elevation of sCD40L levels in serum of obese individuals. Recently, it was demonstrated in atherosclerotic mice that CD40L deficiency reduces hepatosteatosis, adipose tissue infiltration of immune cells, inflammation and weight gain in response to HFD-induced obesity. 10 It is suggested that CD40-CD40L interactions seem to be critical for monocyte activation mediated by ox-LDL and adipocyte interaction with endothelial cells leading to atherothrombotic disease. 25 This is supported by our observation that CD40L deficiency prevents an inflammatory phenotype in HFD-treated mice as envisaged by diminished iNOS and IL-6 expression. In accordance with these findings, it has been shown that CD40L deficiency in obesity and hyperlipidemia sCD40L induces chemokine expression [MCP-1, interleukin-8 (IL-8)] in human umbilical vein endothelial cells (HUVECs), which is accompanied by increased endothelial dysfunction and oxidative stress. [26] [27] [28] The latter phenomenon is mediated in PKC-dependent manner, a protein kinase, which is also known to be responsible for activation of NADPH oxidase, especially phagocytic Nox2. 29 The here reported improvement of endothelial dysfunction in the absence of CD40L is probably a consequence of decreased inflammation-triggered oxidative stress (NADPH oxidase expression and ROS formation by different methods and effects of VAS2870 inhibitor) in the HFD-treated mice, which is a known hallmark in the pathogenesis of hypercholesterolaemia. 30 Therefore, the modest worsening of endothelium-independent relaxation in HFD-treatd mice by CD40L deficiency was unexpected, although the absolute degree of vascular dysfunction (loss of GTN potency), that was induced by HFDtreatment in both mouse strains, was only marginal (only 3-5%). We can currently only speculate that the required bioactivation of GTN by mitochondrial aldehyde dehydrogenase 2, a redox-regulated enzyme, further complicates the interpretation of these data. The here reported dramatic degree of endothelial dysfunction in vessels of db/db mice is similar to the one shown for db/db mice of similar age in previous studies 31, 32 and the improvement of endothelial function by ex vivo treatment of vessel segments with SOD and tetrahydrobiopterin in these previous reports supports the oxidative stress and eNOS uncoupling triggered vascular phenotype of db/db mice. 31, 32 The observation that pharmacological CD40/TRAF6 treatment improved endothelial-dependent (ACh) andindependent (GTN) relaxation in vessels of db/db mice only by trend may be attributed to the fact that the vascular phenotype of these 14-weeks old db/db mice is partly irreversible (e.g. due to remodeling) and CD40/TRAF6 treatment may have been started too late (only for the last 2 weeks before sacrifice). Also increased leptin levels in HFD-treated WT mice may provide an explanation for increased Nox2-derived ROS formation. Serum levels of leptin are not only an accepted cardiovascular risk marker 33 but also seem to trigger Nox2-derived ROS formation by an endothelin-1 receptor-dependent pathway. 34 However, unexpected data on increased weight gain of CD40 -/-mice on a HFD were reported in a recent study, 35 which is either at variance with previous reports on the effects of CD40L signalling on obesity by the same group, 25 or points to alternative targets of CD40L besides CD40 [e.g. a IIb b 3 (CD41/CD61), a 5 b 1 (CD51/CD29), and a M b 2 (CD11b/CD18, Mac-1)]. 13, 36, 37 In our study, CD40L deficiency led to a lower extent of obesity linked to an impaired metabolic profile. This is in accordance with previous reports in a similar model 10 and supports the idea that CD40 ligation directs cholesterol trafficking to sites of lipid oxidation in macrophages, which explains an increase of cholesterol in obese WT mice. 38 These observations are further supported by the protective effects of a CD40/TRAF6 inhibitor (compound 6877002) preventing insulin resistance, immune cell infiltration and tissue inflammation in HFD-treated mice 17 and by our present findings on compound 6877002 beneficial effects in db/db mice. The reduced weight gain in the CD40L deficient HFD-fed group makes the interpretation of data complicated: Is reduced obesity just another beneficial effect of CD40L deficiency that contributes to the overall improvement of the adverse phenotype of obese mice or does CD40L deficiency confer its beneficial cardiovascular, anti-oxidant and anti-inflammatory effects via reduced weight gain? Maybe a part of this question is answered by the minor effect of CD40/TRAF6 inhibition on the absolute weight of db/db mice despite appreciable effects on other parameters.
The clinical study situation is not clear. Although several independent studies showed a correlation between sCD40L and cardiovascular events/diseases (e.g. for unstable angina pectoris, 39 restenosis after stent implantation, 40 degree of hypertension, 9 acute coronary syndrome, 41 and pulmonary hypertension 27 ), these were contradicted by others. 42, 43 Obviously sCD40L correlates with other markers of inflammation but does not represent an independent risk marker for stroke and myocardial infarction. 44 sCD40L was increased in plasma of type 1 diabetes patients but not predictive for overall mortality or cardiovascular events. 45 In summary, a recent meta-analysis demonstrates that among all inflammatory cytokines IL-6 displays the highest hazard-ratio for coronary heart disease (1.37), followed by matrix metalloproteinase-9 (1.30), IL-18 (1.26), TNF-a (1.13), and sCD40L without effect (1.01). 46 It is expected that the CANTOS trial will provide a first answer whether anti-inflammatory therapy with Canakinumab, an IL-1b-antagonizing anti-body, is beneficial in diabetic patients with high cardiovascular risk. 47 Approximately 90% of the circulating sCD40L originate from activated platelets and it is reasonable to assume that obesity-associated vascular inflammation and dysfunction is driven by platelet-derived sCD40L. Systemic therapy with CD40L antagonizing anti-bodies is, however, associated with major bleeding complications. Thus a more selective targeting of the CD40-CD40L (e.g. at the level of TRAFs) might provide more cell or tissue-specific interference points for preventing the pathophysiological role of this pathway in vascular inflammation, oxidative stress and dysfunction. Beneficial effects of pharmacological CD40/ TRAF6 inhibition were previously shown in HFD-treated mice 17 and are also evident in the present study on db/db mice. Although the statistical power of the human study was quite low having only 10 patients per group, there is a clear trend for increased inflammation and oxidative stress in the obese individuals, with an appreciable overlap of expression patterns in our mouse models. sCD40L serum levels were significantly enhanced in the obese group, warranting further human studies in the future to investigate the contribution of CD40-CD40L signalling in obesity-associated cardiovascular disease.
Limitations of the study
Blood glucose and metabolic parameters in the mice were measured under non-fasting conditions. This could explain the variance of the here presented blood glucose levels (see Supplementary material online, Figure S1 ) in comparison to previous reports. 10 On one hand, the 14-week-old db/db mice developed a quite severe vascular phenotype (e.g. highly pronounced endothelial dysfunction), which may represent a limitation of the study since the correlation with the clinical situation could be rather weak. On the other hand, this fact makes our observation that short-term CD40/TRAF6 inhibition partly corrects this adverse phenotype even more impressive.
The DHE fluorescence microtopography in aortic cryo sections is not among the recommended methods for vascular ROS detection in a scientific statement from the American Heart Association. 48 However, besides the notion that DHE staining should not be used in the absence of DNA in the sample (since optimal fluorescence of DHE oxidation products requires DNA intercalation-which will clearly be the case in any tissue sample) and DHE staining is not specific for superoxide if not combined with HPLC separation and detection, we found no other major argument against the use of this assay. In general, DHE staining is considered unspecific but we here combined the assay with specific inhibitors demonstrating that the signal in HFD-treated WT mice can be suppressed by the NADPH oxidase inhibitor VAS2870 and the superoxide scavenging enzyme PEG-SOD ( Figure 2B) . Likewise, endothelial DHE staining in aortic cryo sections of db/db mice was decreased by L-NAME indicating eNOS uncoupling ( Figure 4G) . key data from previous reports supporting the meaningful use of DHE staining in various disease settings. 49 The value and specificity of measurements of NADPH oxidase activity in isolated membrane fractions by lucigenin enhanced chemiluminescence was recently questioned. 50, 51 In general, false-positive increase in superoxide was reported for lucigenin enhanced chemiluminescence. 52 Therefore, the use of this assay needs to be justified in more detail. First, also this assay was supported by strong experimental data collected in our recent review. 49 Second, redox cycling by lucigenin seems to be a major issue under artificial conditions but not in biological samples at low lucigenin concentrations (< _5 mM). 53, 54 Third, in order to justify the use of cardiac membrane fractions for conclusions on the vascular system, we would like to emphasize that measurement of ROS formation in cardiac membrane preparations was mirrored by aortic parameters such as Nox expression and vascular ROS formation (diabetes 55 ; hypertension 56, 57 ). In addition, we have previously shown that NADPH oxidase activity in aortic and cardiac membrane fractions goes in parallel (angiotensin-II infusion model 3 ). The relevance of the present cardiac membrane fraction data is further supported by DHE cryo staining experiments using the NADPH oxidase inhibitor VAS2870 ( Figure 2B) .
Nevertheless, considering the critics we received on our present study, we would like to point out that better assays for ROS detection in biological systems exist (devoid of redox cycling and more specific) and refer to four review articles on state-of-the-art detection methods that should be applied if possible. 48 ,58-60
Conclusions and clinical implications
Our observations provide a link between CD40L triggered endothelial cell activation, 61 vascular oxidative stress, inflammation and dysfunction as well as pro-thrombotic pathways, which may play an important role for CD40L-mediated cardiovascular complications in mouse models of obesity, dyslipidemia, and hyperglycemia. At least, we found some correlations with gene expression in samples from obese human subjects. Based on these considerations therapeutic targeting of the CD40-CD40L interaction and its down-stream signalling pathways (TRAFs) may represent a novel strategy to treat lipid (and potentially glucose) metabolic disorders, [62] [63] [64] [65] which is one leading cause of atherothrombotic cardiovascular diseases like stroke or myocardial infarction. Since CD40L and CD40 are expressed not only by platelets and immune cells but also by endothelial and smooth muscle cells, 66 it remains to be established whether CD40L deficiency (i) simply prevents CD40L release by activated platelets and cross-activation of circulating myelomonocytic cells in obese animals and individuals, or (ii) interrupts the inflammatory cascade in vascular cells (either initiated by CD40-CD40L signalling by infiltrated immune cells or direct activation of vascular CD40 by plateletderived CD40L).
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